Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 18/20 | 0.79 |
| ▸ | NPC1 | O15118 | 17/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.79 |
| ▸ | MAPT | P10636 | 10/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.79 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.79 |
| ▸ | RELA | Q04206 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 14/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.71 |
| ▸ | TP53 | P04637 | 6/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 9/20 | 0.66 |
| ▸ | GFER | P55789 | 3/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.65 |
| ▸ | CASP3 | P42574 | 3/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.62 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424109 | 0.89 | NPC1 (0.80) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL29838123 | 0.89 | NPC1 (0.80) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL2492958 | 0.88 | RAB9A (1.00) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL30153418 | 0.88 | RAB9A (1.00) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL3401206 | 0.88 | RAB9A (0.79) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL2270976 | 0.88 | NPC1 (0.78) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL29858577 | 0.88 | RAB9A (0.79) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL2251836 | 0.88 | RAB9A (0.79) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL29364223 | 0.88 | NPC1 (0.78) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL28578138 | 0.84 | RAB9A (0.73) | RAB9ANPC1KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-10-12 | — | — | US | claimed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | CHDI FOUNDATION, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240150277-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-09 | — | — | US | disclosed |
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-107108534-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | RAB9A 1100/4885NPC1 163/4885KDM4E 4585/4885 |
| US-20240150277-A1 | Covalent PPARG inverse-agonists | PPARG, PPARD, PPARA | RAB9A 1805/4885NPC1 1079/4885KDM4E 3497/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885KDM4E 3311/4885 |
| US-12083108-B2 | Compounds for targeting mutant huntingtin protein and uses thereof | HTT, HYPK, UBQLN2 | RAB9A 1054/4885NPC1 1066/4885KDM4E 2698/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | RAB9A 3748/4885NPC1 2477/4885KDM4E 3311/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | RAB9A 4325/4885NPC1 3637/4885KDM4E 2080/4885 |
| US-20240109850-A1 | Covalent PPARG inverse-agonists | PPARG, PPARD, PPARA | RAB9A 1805/4885NPC1 1079/4885KDM4E 3497/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | RAB9A 1100/4885NPC1 163/4885KDM4E 4585/4885 |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | RAB9A 993/4885NPC1 112/4885KDM4E 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.